Screener
McKesson MCK Oncology & Multispecialty — Foreign currency translation adjustments, net
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | North American Pharmaceutical | Oncology & Multispecialty | Prescription Technology Solutions | Medical-Surgical Solutions | Total |
|---|---|---|---|---|---|
| Balance, March 31, 2026 | $2,781 | $3,963 | $2,065 | $2,507 | $11,316 |
| Goodwill acquired | — | 13 | — | — | 13 |
| Disposals | — | (2) | — | — | (2) |
| Foreign currency translation adjustments, net | (26) | — | — | — | (26) |
| Other adjustments (1) | — | (23) | — | — | (23) |
| Balance, June 30, 2026 | $2,755 | $3,951 | $2,065 | $2,507 | $11,278 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's oncology & multispecialty — foreign currency translation adjustments, net?
- McKesson (MCK) reported oncology & multispecialty — foreign currency translation adjustments, net of $0 in Q2 2026.
- What does oncology & multispecialty — foreign currency translation adjustments, net mean?
- The net impact of fluctuations in foreign exchange rates on the valuation of assets and liabilities denominated in currencies other than the reporting currency for this segment. This captures the volatility inherent in international operations within the oncology and multispecialty business.
Ask your AI about McKesson's oncology & multispecialty — foreign currency translation adjustments, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude